Brief: Intervacc Says U.S. Patent Approval For Co's Vaccine Against Infections Caused By Streptococcus Suis

Intervacc AB

08/11/2021 20:30

Nov 8 (Reuters) - Intervacc AB  IVACC.ST :
    * U.S. PATENT APPROVAL FOR INTERVACC'S VACCINE AGAINST
INFECTIONS
CAUSED BY STREPTOCOCCUS SUIS
    * INTERVACC AB  -  U.S. PATENT NO. 11,155,585 RELATES TO A
VACCINE
BASED ON RECOMBINANT FUSION PROTEINS WHERE PATENT PROTECTION IS
EFFECTIVE UNTIL 2037

Source text for Eikon:  ID:nWkr4CLgyv 
Further company coverage:  IVACC.ST 

 ((Reuters.Briefs@thomsonreuters.com;))